|
Enochian Biosciences Inc. is a biopharmaceutical levering its gene therapy platform to treat patients with HIV/AIDS. The company has a diverse pipeline at the preclinical and discovery stage to treat and prevent infectious disease and cancer. In the infectious disease front, there are two key products i) the lead candidate, genetically modified cell therapy ENO-1001, that is currently at preclinical stage for treatment of patients with HIV/AIDS and ii) ENO-2001, a vaccine, to prevent HIV infection. In the oncology front, Enochian is developing agents ENO-1002, ENO-3001, and ENO-5001 to treat patients with relapse metastatic colon cancer. The company has established research and development agreements with Scripps Research Institute to conduct pre-new drug application (pre-IND) work to advance ENO-1001 in the clinic, and with University of California Los Angles (UCLA) to advance HIV program. Enochian BioSciences is headquartered in Los Angeles, California.
Link to Enochian page on Channelchek
|
